To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH

NCT05997602 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Langerhans Cell Histiocytosis
LCH

Interventions

DRUG: FCN-159

Sponsor

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.